The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Month: May 2022

Ethical challenges in microbiome research
Pharma & Human Health

Ethical challenges in microbiome research

MAY 24, 2022
Phage therapy: A model to predict its efficacy against pathogenic bacteria
Infectious Disease & AMR

Phage therapy: A model to predict its efficacy against pathogenic bacteria

MAY 23, 2022
Researchers use virus to fight bacterial infection clearing way for life-saving lung transplant
Infectious Disease & AMR

Researchers use virus to fight bacterial infection clearing way for life-saving lung transplant

MAY 17, 2022
A refined microbiome “fingerprint” method tracks sub-strain variants of a single gut microbe strain
Pharma & Human Health

A refined microbiome “fingerprint” method tracks sub-strain variants of a single gut microbe strain

MAY 9, 2022
Study finds how Acinetobacter baumannii survives without water on hospital surfaces
Infectious Disease & AMR

Study finds how Acinetobacter baumannii survives without water on hospital surfaces

MAY 5, 2022
New method for probing the bewildering diversity of the microbiome
Pharma & Human Health

New method for probing the bewildering diversity of the microbiome

MAY 5, 2022
Microba Accelerates Cancer Program with New Leads
Oncology

Microba Accelerates Cancer Program with New Leads

MAY 5, 2022
Pherecydes Pharma Announces the First International Approval of a Compassionate Treatment With Its Phages
Infectious Disease & AMR

Pherecydes Pharma Announces the First International Approval of a Compassionate Treatment With Its Phages

MAY 3, 2022